
PROTHENA CORP PUBLIC LTD CO — Investor Relations & Filings
Prothena Corporation is a late-stage clinical biotechnology company specializing in the science of protein dysregulation. The company leverages its expertise in the biology of misfolded proteins to discover and develop novel therapeutics. Its primary focus is on advancing a diverse pipeline of investigational treatments for neurodegenerative conditions and rare peripheral amyloid diseases. Prothena's scientific approach integrates insights into neurological dysfunction and the mechanisms of protein misfolding to create antibody-based therapies designed to provide clinically meaningful benefits for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-15 | English | |
| DEF 14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-03-27 | English | |
| 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | |
| 10-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | |
| 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-19 | English | |
| 8-K | 2025-12-12 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
5 filings
| |||||
| 46362587 | 8-K | 2026-05-15 | English | ||
| 33065546 | DEF 14A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-03-27 | English | ||
| 32893883 | 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | ||
| 32893885 | 10-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-27 | English | ||
| 32893884 | 8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer) | 2026-02-19 | English | ||
|
2025
10 filings
| |||||
| 12590207 | 8-K | 2025-12-12 | English | ||
| 12590208 | 8-K | 2025-11-19 | English | ||
| 12590209 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 12590210 | Major Shareholding Notification 2025 | 2025-11-12 | English | ||
| 12590211 | Major Shareholding Notification 2025 | 2025-11-12 | English | ||
| 12590212 | 10-Q | 2025-11-06 | English | ||
| 12590213 | DEFA14A | 2025-11-06 | English | ||
| 12590214 | 8-K | 2025-11-06 | English | ||
| 12590215 | Major Shareholding Notification 2025 | 2025-10-17 | English | ||
| 12590216 | DEFA14A | 2025-10-07 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CHAMPIONS ONCOLOGY, INC.
A CRO providing end-to-end solutions to accelerate oncology…
|
CSBR | US | Professional, scientific and te… |
|
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
A contract research organization supporting drug discovery …
|
CRL | US | Professional, scientific and te… |
|
ChemPartner PharmaTech Co., Ltd.
Global CRO and CDMO providing integrated drug discovery and…
|
300149 | CN | Professional, scientific and te… |
|
CHIMERIC THERAPEUTICS LIMITED
Clinical-stage cell therapy company developing CAR T and NK…
|
CHM | AU | Professional, scientific and te… |
|
China National Electric Apparatus Research Institute Co., Ltd.
R&D institution for electrical and electronics testing, equ…
|
688128 | CN | Professional, scientific and te… |
|
Chiome Bioscience Inc.
Clinical-stage biotech company developing antibody-based th…
|
4583 | JP | Professional, scientific and te… |
|
CHITOGENX INC
Clinical stage regenerative medicine company focused on nov…
|
CHGX | CA | Professional, scientific and te… |
|
Chordate Medical Holding AB
Develops a patented, drug-free neuromodulation treatment fo…
|
CMH | SE | Professional, scientific and te… |
|
Chordia Therapeutics,Inc
Clinical-stage biotech developing novel cancer therapies ta…
|
190A | JP | Professional, scientific and te… |
|
Cibus, Inc.
Develops and licenses plant traits using non-GMO precision …
|
CBUS | US | Professional, scientific and te… |
PROTHENA CORP PUBLIC LTD CO via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32782/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32782 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32782 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32782 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32782}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PROTHENA CORP PUBLIC LTD CO (id: 32782)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.